Everly Health Acquires Women’s Health Startup Natalist

The conception and pregnancy startup is the third company to be acquired this year by Everlywell’s parent company.

Written by Jeff Rumage
Published on Oct. 21, 2021
Everly Health Acquires Women’s Health Startup Natalist
Natalist's product suite supports women from pre-conception through pregnancy and includes tests, supplements, education, lubricants, and self-care items.
photo: everly health

Everly Health, an Austin-based healthtech company, announced Thursday that it has acquired Natalist, a women’s health company that focuses on pregnancy and conception. 

Halle Tecco founded Natalist in 2019 after her own struggle with getting pregnant. She assembled a team of moms and doctors to reduce the shame, misinformation and outdated product offerings they all experienced on their pregnancy journey. 

Natalist’s most popular products are its ovulation tests, pregnancy tests and prenatal supplements. The company also offers lubricants and educational materials. Its products can be found online and in nearly 6,000 brick-and-mortar retail locations. 

“Natalist was created to serve people who are seeking modern, sustainable tools for conception and pregnancy. Everly Health’s full capabilities across testing, telehealth, and virtual care delivery will supercharge our ability to help people in ways we’re only beginning to explore,” Natalist CEO Vernita Brown said in a statement. “I’m thrilled to discover what we can accomplish together, as part of Everly Health.” 

Natalist is Everly Health’s third acquisition this year. The terms of the all-cash transaction were not disclosed.

With this acquisition, Everly Health will grow to four subsidiaries: Everlywell, EverlyDx, Everly Health Solutions and Natalist. 

Everly Health, the parent company of diagnostic testing startup Everlywell, was formed in March, when Everlywell acquired PWNHealth and Home Access Health Corporation. Everlywell is well known for its at-home testing kits for concerns including food sensitivity, allergies and thyroid hormone levels.

Two months prior to those acquisitions, Everlywell raised $75 million on top of its $175 million Series D funding, bringing the round to $250 million and its overall fundraising to more than $325 million.

Natalist’s products expand Everlywell’s existing suite of at-home women’s health tests for menopause, fertility hormones and sexual health. 

“Creating innovative solutions for women’s health was my initial motivation for founding Everlywell and remains a top area of focus,” Everly Health founder and CEO Julia Cheek said in a statement. “A survey of our customers revealed that nearly 70 percent don’t trust many of the women’s health products available on the market today. Natalist’s thoughtfully designed fertility and pregnancy essentials are the solution that so many women are seeking.” 

Hiring Now
Q2
Fintech • Software • Financial Services